Immunoassays

Wednesday, 08 April, 2009 | Supplied by: Merck Pty Ltd


Novagen has introduced multiplex immunoassays for the bead-based Luminex xMAP Technology platform. The range of immuno-assays allows the multiplex quantification of phosphorylated proteins, giving researchers the opportunity to examine changes in cellular signalling that reflect disease states or various drug treatments.

The WideScreen EpiTag assays detect key signalling events in the ERK pathway from both human and mouse samples.

WideScreen RTK assays allow the simultaneous determination of tyrosine phosphorylation status of several key receptor tyrosine kinases.

The WideScreen Human Cancer Panel 1 provides the quantitative detection of six cancer-associated proteins found in biological fluids.

The WideScreen Human Cancer Panel provides quantitative detection of 12 human growth factors found in biological fluids.

The WideScreen Human Cardiovascular Disease Panel 1 provides quantitative detection of seven human apolipoproteins.

Finally, the WideScreen Human Cardiovascular Disease Panel 2 provides quantitative detection of six human cytokines/chemokines associated with cardiovascular disease.

Online: www.sigmaaldrich.com/AU/en
Phone: 1800 800 097
Related Products

Mercodia Insulin MBeads Assay

The assay is designed to offer high accuracy by specifically measuring human insulin while...

Waters BD FACSDiscover A7 Cell Analyzer

The BD FACSDiscover A7 Cell Analyzer combines high spectral resolution and sensitivity with...

Lumiprobe CytoTracer fluorescent cell dyes

The dyes rapidly penetrate cells, form intracellular membrane-impermeable products, and deliver...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd